Shots:
- Areteia Therapeutics has reported P-III (EXHALE-4) trial data assessing dexpramipexole (75 or 150mg, PO, BID) vs PBO as an add-on therapy to treat pts (n=600; ≥12yrs.) with inadequately controlled moderate-to-severe asthma & blood AEC ≥300 cells/μL
- Trial showed that 150mg improved lung function over Wks. 20 & 24 (1EP), as measured by pre-BD FEV1 change, with benefits seen as early as Wk. 4, plus both doses significantly reduced blood AEC over Wks. 20–24; full data to be presented in a future meeting
- Dexpramipexole is being studied in P-III (EXHALE-2 & EXHALE-3) trials for eosinophilic asthma, with enrolment ongoing in both
Ref: Novo Businesswire | Image: Areteia Therapeutics | Press Release
Related News:- Novo Nordisk Reveals P-III (REDEFINE 1) Trial Data of Cagrilintide for Weight Loss in Obese/Overweight
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
